PT Kedoya Adyaraya Tbk (RSGK.JK)
IDR 990.0
(-1.0%)
IDR 990.0
(-1.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 25.18 Billion IDR | -3.79% |
| 2022 | 26.17 Billion IDR | -50.52% |
| 2021 | 52.9 Billion IDR | 1922.57% |
| 2020 | 2.61 Billion IDR | -33.54% |
| 2019 | 3.93 Billion IDR | -69.06% |
| 2018 | 12.72 Billion IDR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 15.42 Billion IDR | 126.12% |
| 2024 Q3 | 8.24 Billion IDR | -16.67% |
| 2024 Q2 | 9.89 Billion IDR | -35.82% |
| 2023 Q2 | 6.38 Billion IDR | -18.83% |
| 2023 Q1 | 7.86 Billion IDR | 33.65% |
| 2023 FY | 25.18 Billion IDR | -3.79% |
| 2023 Q4 | 6.82 Billion IDR | 65.88% |
| 2023 Q3 | 4.11 Billion IDR | -35.63% |
| 2022 Q3 | 11.64 Billion IDR | 662.65% |
| 2022 Q2 | -2.07 Billion IDR | -119.43% |
| 2022 FY | 26.17 Billion IDR | -50.52% |
| 2022 Q1 | 10.65 Billion IDR | 163.06% |
| 2022 Q4 | 5.88 Billion IDR | -49.45% |
| 2021 Q1 | 29.06 Billion IDR | 102.37% |
| 2021 FY | 52.9 Billion IDR | 1922.57% |
| 2021 Q4 | -16.89 Billion IDR | -257.82% |
| 2021 Q3 | 10.7 Billion IDR | -64.2% |
| 2021 Q2 | 29.9 Billion IDR | 2.91% |
| 2020 Q4 | 14.36 Billion IDR | 0.0% |
| 2020 FY | 2.61 Billion IDR | -33.54% |
| 2019 FY | 3.93 Billion IDR | -69.06% |
| 2018 FY | 12.72 Billion IDR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| PT Bundamedik Tbk | 7.46 Billion IDR | -237.601% |
| PT Metro Healthcare Indonesia Tbk | -110.91 Billion IDR | 122.709% |
| PT Medikaloka Hermina Tbk | 437.34 Billion IDR | 94.241% |
| PT Mitra Keluarga Karyasehat Tbk | 916.13 Billion IDR | 97.251% |
| PT Murni Sadar Tbk | -12.83 Billion IDR | 296.3% |
| PT Famon Awal Bros Sedaya Tbk | 216.97 Billion IDR | 88.391% |
| PT Royal Prima Tbk | -2.74 Billion IDR | 1017.124% |
| PT Sarana Meditama Metropolitan Tbk | 12.25 Billion IDR | -105.586% |
| PT Siloam International Hospitals Tbk | 1211.28 Billion IDR | 97.92% |
| PT Sejahteraraya Anugrahjaya Tbk | -38.49 Billion IDR | 165.443% |